The trials are planned to begin in medical centers in Israel and in the US as soon as local regulatory approvals and agreements with the medical centers are concluded. Tikcro holds shares, warrants and convertible debt of Biocancell.
For ovarian cancer, BC-819 will be administered intraperitoneally to 12 patients. Each patient will receive nine weekly treatments. The trial follows a compassionate use trial conducted in Israel with a patient suffering from ovarian cancer characterized by intraperitoneal distribution of metastases and ascites, after the failure of conventional chemotherapy treatment.
The results of the trial show that the drug caused no serious adverse events at any dosage, and that a decrease of 50% in the ovarian cancer marker protein CA-125 in the patient’s blood was measured, as well as a significant decrease in the number of cancerous cells in the ascites, and reports of a clinical improvement in the patient’s condition. The patient’s quality of life was increased during the course of the treatment.
For pancreatic cancer, BC-819 will be administered intratumorally to six to nine patients. Each patient will receive a total of four treatments over the course of two weeks. The Virginia Biosciences Development Center is BioCancell’s US partner for conducting this trial.
The trial follows preclinical studies that showed that when a group of hamsters was treated with BC-819 and compared to a control group, primary pancreatic tumor volume in the treated group was significantly reduced as compared with those in the control group, and that tumor growth progression was significantly reduced in the treated group as compared with the control group. In addition, it was shown that one-third of the treated group showed metastases, compared to 100% of the control group.